Fecal Calprotectin in Children Can Differentiate Between Different Gastrointestinal Diseases

Authors

  • Yasser Rashed Department of Pediatric Hepatology, Gastroenterology and Nutrition, NationalLiver Institute, Menoufiya University, Al Minufiyah, Egypt https://orcid.org/0000-0001-9484-1238

DOI:

https://doi.org/10.3889/oamjms.2022.8367

Keywords:

Fecal calprotectin, Inflammatory bowel disease, Eosinophilic esophagitis, Celiac disease, Helicobacter pylori infection, Functional constipation

Abstract

BACKGROUND: Calprotectin is a 36 kDa member of the S100 family of proteins. It is derived predominantly from neutrophils and has direct antimicrobial effects and a role within the innate immune response. Calprotectin is found in various body fluids in proportion to the degree of any existing inflammation and its concentration in feces is about 6 times that of plasma. Measurement of fecal calprotectin is a useful surrogate marker of gastrointestinal inflammation. It has a high negative predictive value in ruling out inflammatory bowel disease (IBD) in undiagnosed, symptomatic patients and high sensitivity for diagnosing the disease making it useful as a tool for prioritizing endoscopy. In patients with known IBD, fecal calprotectin can be a useful tool to assist management, providing evidence of relapse or mucosal healing to enable therapy to be intensified or reduced.

AIM: The present study aimed to discuss the use of calprotectin for the diagnosis of IBD and some of the other ways in which the test may be useful in the management of gastroenterology patients.

METHODS: A cross-sectional study on children with significant gastrointestinal diseases attending to pediatric department at Menoufia University, with a total number of 180 patients in addition to 30 normal children as control according to sample size calculation. The children are allocated into seven groups according to the final diagnosis to Group (1): 30 patients with IBD, Group (2): 20 patients with eosinophilic colitis, Group (3): 30 patients with Helicobacter pylori infection, Group (4): 40 patients with functional constipation, Group (5): 30 patients with cow milk allergy, Group (6): 30 patients with Celiac disease, and Group (7): 30 normal children as control.

RESULTS: In cow milk protein allergic patients with marked GI presentation in the form of bloody diarrhea and/or abdominal distension, the mean fecal calprotectin (FC) was 1260 ± 625 μg/g. FC has decreased after 2−4 weeks of elimination of cow milk products to 420 ± 190 μg/g. Patient with inflammatory bowel disease had mean FC 4640 ± 850 μg/g, decreased after medical treatment and resolution of symptoms to 1360 ± 520 μg/g. In H. pylori infection detected by upper GI endoscopy and histopathology with positive stool antigen the mean FC was 78.9 ± 25.1 μg/g. Celiac disease patients had mean fecal calprotectin 456 ± 123 μg/g. Eosinophilic esophagitis had mean fecal calprotectin 4.2 ± 2.9 μg/g. Functional constipation patients had mean fecal calprotectin 23.6 ± 21.8 μg/g. Normal control children had mean fecal calprotectin 4.1 ± 6.9 μg/g.

CONCLUSION: According to the results of previous studies, fecal calprotectin can be considered as a biomarker to differentiate between IBS and organic gastrointestinal disorders. However, due to the limitations of pre-analysis, a low fecal calprotectin concentration may not necessarily be considered as the reason for the absence of IBD.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Mumolo MG, Bertani L, Ceccarelli L, Laino G, Di Fluri G, Albano E, et al. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. World J Gastroenterol. 2018;24(33):3681. https://doi.org/10.3748/wjg.v24.i33.3681 PMid:30197475 DOI: https://doi.org/10.3748/wjg.v24.i33.3681

Yoo IH, Cho JM, Joo JY, Yang HR. Fecal calprotectin as a useful non-invasive screening marker for eosinophilic gastrointestinal disorder in Korean children. J Korean Med Sci. 2020;35(17):e120. https://doi.org/10.3346/jkms.2020.35.e120 PMid:32356420 DOI: https://doi.org/10.3346/jkms.2020.35.e120

Balamtekın N, Baysoy G, Uslu N, Orhan D, Akçören Z, Özen H, et al. Fecal calprotectin concentration is increased in children with celiac disease: Relation with histopathological findings. Turk J Gastroenterol. 2012;23(5):503-8. https://doi.org/10.4318/tjg.2012.0366 PMid:23161294 DOI: https://doi.org/10.4318/tjg.2012.0366

Capone P, Rispo A, Imperatore N, Caporaso N, Tortora R. Fecal calprotectin in coeliac disease. World J Gastroenterol. 2014;20(2):611. https://doi.org/10.3748/wjg.v20.i2.611 PMid:24574734 DOI: https://doi.org/10.3748/wjg.v20.i2.611

Fahim SM, Das S, Gazi MA, Alam MA, Hasan MM, Hossain MS, et al. Helicobacter pylori infection is associated with fecal biomarkers of environmental enteric dysfunction but not with the nutritional status of children living in Bangladesh. PLoS Negl Trop Dis. 2020;14(4):e0008243. https://doi.org/10.1371/journal.pntd.0008243 PMid:32324737 DOI: https://doi.org/10.1371/journal.pntd.0008243

Kalach N, Bontems P, Raymond J. Helicobacter pylori infection in children. Helicobacter. 2017;22(1):e12414. https://doi.org/10.1111/hel.12414 PMid:28891139 DOI: https://doi.org/10.1111/hel.12414

Demirbaş F, Çaltepe G, Abbasguliyev H, Kalaycı AG. Fecal calprotectin levels used as a noninvasive method for screening for chronic gastritis in pediatric patients. A descriptive study. Sao Paulo Med J. 2021;139(6):564-9. https://doi.org/10.1590/1516-3180.2020.0765.R1.0904221 PMid:34406311 DOI: https://doi.org/10.1590/1516-3180.2020.0765.r1.0904221

Beşer ÖF, Sancak S, Erkan T, Kutlu T, Çokuğraş H, Çokuğraş FÇ. Can fecal calprotectin level be used as a markers of inflammation in the diagnosis and follow-up of cow’s milk protein allergy? Allergy Asthma Immunol Res. 2014;6(1):33-8. https://doi.org/10.4168/aair.2014.6.1.33 PMid:24404391 DOI: https://doi.org/10.4168/aair.2014.6.1.33

Lee SH, Mainman H, Borthwick H, Dhar A. PTH-094 faecal calprotectin testing in primary and secondary care-are the current manufacturer’s cut-off levels clinically useful? Gut. 2013;62(1):A249-9. DOI: https://doi.org/10.1136/gutjnl-2013-304907.581

Komraus M, Wos H, Wiecek S, Kajor M, Grzybowska-Chlebowczyk U. Usefulness of faecal calprotectin measurement in children with various types of inflammatory bowel disease. Mediators Inflamm. 2012;2012:608249. DOI: https://doi.org/10.1155/2012/608249

Dale I. Plasma levels of the calcium-binding Li leukocyte protein: Standardization of blood collection and evaluation of reference intervals in healthy controls. Scand J Clin Lab Invest. 1990;50(8):837-41. https://doi.org/10.3109/00365519009104950 PMid:2128131 DOI: https://doi.org/10.3109/00365519009104950

Dunlop O, Bruun JN, Myrvang B, Fagerhol MK. Calprotectin in cerebrospinal fluid of the HIV infected: A diagnostic marker of opportunistic central nervous system infection? Scand J Infect Dis. 1991;23(6):687-9. https://doi.org/10.3109/00365549109024294 PMid:1815329 DOI: https://doi.org/10.3109/00365549109024294

Mao R, Xiao YI, Gao X, Chen BL, He Y, Yang L, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18(10):1894-9. https://doi.org/10.1002/ibd.22861 PMid:22238138 DOI: https://doi.org/10.1002/ibd.22861

Shitrit AB, Braverman D, Stankiewics H, Shitrit D, Peled N, Paz K. Fecal calprotectin as a predictor of abnormal colonic histology. Dis Colon Rectum. 2007;50(12):2188-93. https://doi.org/10.1007/s10350-007-9038-x PMid:17963005 DOI: https://doi.org/10.1007/s10350-007-9038-x

Fagerberg UL, Lööf L, Myrdal U, Hansson LO, Finkel Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr. 2005;40(4):450-5. https://doi.org/10.1097/01.mpg.0000154657.08994.94 PMid:15795593 DOI: https://doi.org/10.1097/01.MPG.0000154657.08994.94

Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140(6):1817- 26. https://doi.org/10.1053/j.gastro.2010.11.058 PMid:21530748 DOI: https://doi.org/10.1053/j.gastro.2010.11.058

Montalto M, Gallo A, Santoro L, D’Onofrio F, Landolfi R, Gasbarrini A. Role of fecal calprotectin in gastrointestinal disorders. Eur Rev Med Pharmacol Sci. 2013;17(12):1569-82. PMid:23832721

Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol Pharm Bull. 2003;26(6):753-60. https://doi.org/10.1248/bpb.26.753 PMid:12808281 DOI: https://doi.org/10.1248/bpb.26.753

Fagerberg UL, Lööf L, Lindholm J, Hansson LO, Finkel Y. Fecal calprotectin: A quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;45(4):414-20. https://doi.org/10.1097/MPG.0b013e31810e75a9 PMid:18030206 DOI: https://doi.org/10.1097/MPG.0b013e31810e75a9

Weil D, Heurgue-Berlot A, Monnet E, Chassagne S, Cervoni JP, Feron T, et al. Accuracy of calprotectin using the quantum blue reader for the diagnosis of spontaneous bacterial peritonitis in liver cirrhosis. Hepatol Res. 2019;49(1):72-81. https://doi.org/10.1111/hepr.13239 PMid:30084186 DOI: https://doi.org/10.1111/hepr.13239

Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35(9):642-7. https://doi.org/10.1016/s1590-8658(03)00381-5 PMid:14563186 DOI: https://doi.org/10.1016/S1590-8658(03)00381-5

Shalaby MN, Sakoury MM, Abdi E, Elgamal S, Elrkbwey S, Ramadan W, et al. The impact of resistance training on gene expression of IGF1 and athletes’ physiological parameters. Open Access Macedon J Med Sci. 2021;9(A):934-40. https://doi.org/10.3889/oamjms.2021.7215 DOI: https://doi.org/10.3889/oamjms.2021.7215

Downloads

Published

2022-03-10

How to Cite

1.
Rashed Y. Fecal Calprotectin in Children Can Differentiate Between Different Gastrointestinal Diseases. Open Access Maced J Med Sci [Internet]. 2022 Mar. 10 [cited 2024 Mar. 28];10(B):773-8. Available from: https://oamjms.eu/index.php/mjms/article/view/8367